Abstract
Purpose
To assess the prognostic and predictive value of circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) irrespective of detection level.
Materials and methods
We evaluated the prognostic and predictive significance of CTC count at baseline and under treatment in 119 mCRC subjects and compared the standard cutoff (≥3 CTCs/7.5 mL to ≥1 CTCs/7.5 mL).
Results
An overall comparison was made between patients with 0, 1–2 and ≥3 CTC (median PFS 8, 4 and 5 months, respectively). Two poor prognostic groups were found, including patients with ≥1 CTCs before and during treatment and patients with 0 CTC at baseline who converted to ≥1 CTCs (p = 0.014).
Conclusions
The presence of at least 1 CTC at baseline count is predictive for poor prognosis in mCRC patients. Patients with 1–2 CTC should be switched from the favorable prognostic group—conventionally defined by the presence of <3 CTC—to the unfavorable, deserving a more careful monitoring.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alix-Panabières C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59(1):110–118. doi:10.1373/clinchem.2012.194258
Allard WJ, Matera J, Miller MC et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20):6897–6904. doi:10.1158/1078-0432.CCR-04-0378
Barbazán J, Alonso-Alconada L, Muinelo-Romay L et al (2012) Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PLoS ONE 7(7):e40476. doi:10.1371/journal.pone.0040476
Bidard FC, Ferrand FR, Huguet F et al (2012) Disseminated and circulating tumor cells in gastrointestinal oncology. Crit Rev Oncol Hematol 82(2):103–115. doi:10.1016/j.critrevonc.2011.05.008
Cohen SJ, Punt CJ, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26(19):3213–3221. doi:10.1200/JCO.2007.15.8923
Cohen SJ, Punt CJ, Iannotti N et al (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20(7):1223–1229. doi:10.1093/annonc/mdn786
Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791. doi:10.1056/NEJMoa040766
de Bono JS, Scher HI, Montgomery RB et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309. doi:10.1158/1078-0432.CCR-08-0872
De Mattos-Arruda L, Dienstmann R, Tabernero J (2011) Development of molecular biomarkers in individualized treatment of colorectal cancer. Clin Colorectal Cancer 10(4):279–289. doi:10.1158/1078-0432.CCR-08-0872
Gazzaniga P, Raimondi C, Gradilone A et al (2011) Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero. Ann Oncol 22(8):1929–1930. doi:10.1093/annonc/mdr292
Parkinson DR, Dracopoli N, Petty BG et al (2012) Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 10:138. doi:10.1186/1479-5876-10-138
Sastre J, Maestro ML, Gómez-España A et al (2012) Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist 17(7):947–955. doi:10.1634/theoncologist.2012-0048
Tol J, Koopman M, Miller MC et al (2010) Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 21(5):1006–1012. doi:10.1093/annonc/mdp463
Troiani T, Martinelli E, Morgillo F et al (2013) Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? Ther Adv Med Oncol 5(1):51–72. doi:10.1177/1758834012462462
Acknowledgments
This study is dedicated to Fabio, with love, to keep a promise.
Conflict of interest
Authors disclaim no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
P. Gazzaniga and C. Raimondi have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Gazzaniga, P., Raimondi, C., Gradilone, A. et al. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?. J Cancer Res Clin Oncol 139, 1411–1416 (2013). https://doi.org/10.1007/s00432-013-1450-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-013-1450-0